Familial effects on the clinical course of multiple sclerosis
Anke Hensiek(University of Cambridge), D. A. S. Compston(University of Cambridge), David R. Booth(Hammersmith Hospital), László Vécsei(University of Szeged), Maurizio Leone(Mario Negri Institute for Pharmacological Research), Oluf Andersen(University of Gothenburg), Jan Hillert(Karolinska University Hospital), Shaun R. Seaman(Max Planck Society), Krisztina Bencsik(University of Szeged), Hanne F. Harbo, Kjell‐Morten Myhr, Per Soelberg Sørensen(University of Copenhagen), Robert Heard, M. Eraksoi(University of Copenhagen), Cecília Rajda(University of Szeged), Lisa F. Barcellos(University of California, San Francisco), Frauke Zipp(Johannes Gutenberg University Mainz), Elisabeth Gulowsen Celius(Oslo University Hospital), Eleonora Cocco(University of Cagliari), Jorge R. Oksenberg(University of California, San Francisco), Bénédicte Dubois(University of California, San Francisco), Annette Oturai, Graeme J. Stewart, Stephen L. Hauser(University of California, San Francisco), J. Bellman-Strobl(University of Copenhagen), Stephen Sawcer(University of Cambridge), Maria Giovanna Marrosu(University of Cagliari)
Cited by 90
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
|Nature|2011|2.8k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k